Bitstamp Announces Partnership With Stripe To Streamline Crypto Purchases in EU
09 Aug
Science & Technology

Bitstamp Announces Partnership With Stripe To Streamline Crypto Purchases in EU

Posted by author-avatar
0
Technology tamfitronics Crypto exchange Bitstamp has partnered with Stripe to launch its crypto on-ramp solution in Europe. The partnership will simplify the process of buying crypto with fiat currencieslike the euro and US dollar, for European consumers. In June, Stripe announced the partnership with Coinbaseadding $USDC payments on Base. Bitstamp has partnered with the fintech platform Stripe to make crypto payments more accessible in Europe. Let’s see how the collaboration will benefit European users.Stripe’s On-Ramp TechnologyLaunched in May 2023, Stripe’s fiat-to-crypto on-ramp technology allows users to buy crypto with a card, Apple Pay, or bank transfer. In July, Stripe expanded its fiat-to-crypto on-ramp to the European market.Stripe offers two implementation options for its onramp feature: an embeddable widget and a Stripe-hosted checkout via a link.On August 7, Bitstamp teamed with Stripe...
Continue reading
Menarini Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Efficacy, Safety and Tolerability of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia, Business News
31 Jul
Business News

Menarini Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Efficacy, Safety and Tolerability of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia, Business News

Posted by author-avatar
0
Business new tamfitronics --Achieved primary endpoint of LS mean reduction in LDL-C on top of maximally tolerated lipid modifying therapies at week 12 with statistically significant reduction (p<0.0001), which was sustained at week 52 (p<0.0001) -- -- Obicetrapib lowered LDL-C by 36.3% at week 12 and by 41.5% at week 52, compared to placebo -- -- Obicetrapib was well-tolerated; safety results comparable to placebo-- FLORENCE, Italy, July 29, 2024 /PRNewswire/ -- Menarini Group today announces positive topline data from the Phase 3 BROOKLYN clinical trial (NCT05425745) sponsored by NewAmsterdam Pharma Company N.V. ("NewAmsterdam"), a biopharmaceutical company which granted the Menarini Group an exclusive license to commercialize obicetrapib...
Continue reading
Doubleview Announces Drilling at the Hat Polymetallic Deposit
29 Jul
Top Stories

Doubleview Announces Drilling at the Hat Polymetallic Deposit

Posted by author-avatar
0
Top Stories Tamfitronics Vancouver, British Columbia--(ACN Newswire - July 29, 2024) - Doubleview Gold Corp (TSXV: DBG)(OTCQB: DBLVF) (FSE: A1W038) ("Doubleview" or the "Company") is pleased to announce resumption of drilling at its Hat Project in Northern British Columbia where, prior to a short worker relief stoppage, work had included 3,460 metres of drilling. As detailed below, current work builds upon the extensive database of technical and statistical models used in preparation of the Company's first Mineral Resource Estimate ("MRE - V1") that was announced last week.The Mineral Resource Estimate reported:Micon International Limited authored the MRE and fulfilled the criteria for an MRE to meet the definition of potentially economic extraction.An indicated resource of 150 million tonnes (Mt) and an inferred resource of 477 Mt at 0.2% copper equivalent ("CuEq**") cut-off grade* or An indicated...
Continue reading
Rover Announces $0.03 Unit Financing
29 Jul
Top Stories

Rover Announces $0.03 Unit Financing

Posted by author-avatar
0
Top Stories Tamfitronics Vancouver, BC, July 29, 2024 - (ACN Newswire) - Rover Critical Minerals Corp. (TSXV:ROVR)(OTCQB:ROVMF)(FSE:4XO)("Rover" or the "Company") is pleased to announce a non-brokered private placement financing for a minimum of $175,000 and a maximum of $500,000. The Company will issue $0.03 units. Each unit is priced at $0.03 and is comprised of one common share and one common share purchase warrant (the "$.03 Units"). The warrants on the Units have an exercise price of $0.05 per warrant share, with a life of two years. Assuming the financing is fully subscribed, there will be up to 16,666,667 common shares and 16,666,667 common share purchase warrants issued in connection with this financing, plus any finder's commission warrants.The Company anticipates multiple closings of the $0.03 Unit financing. An updating release will be provided once the Company...
Continue reading
Load more posts
Loading...